6-Cyclohexyl-4-oxo-2-thioxo-DHPM-5-carbonitrile: Synthesis & Use Protocol
6-Cyclohexyl-4-oxo-2-thioxo-DHPM-5-carbonitrile: Synthesis & Use Protocol
6-Cyclohexyl-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile is a structurally distinctive dihydropyrimidine (DHPM) building block bearing a thioxo group at C-2 and a carbonitrile substituent at C-5, making it a versatile heterocyclic intermediate for medicinal chemistry and synthetic research applications.
- Chemical Name
- 6-Cyclohexyl-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile
- SKU / Catalog Number
- C699963
- Core Scaffold
- 3,4-Dihydropyrimidine-2(1H)-thione (DHPM-thione)
- Key Functional Groups
- Thioxo (C=S) at C-2, oxo (C=O) at C-4, nitrile (C≡N) at C-5, cyclohexyl at C-6
- Recommended Storage
- Cool, dry, well-ventilated location; away from moisture and light; refer to SDS for full conditions
- Typical Application
- Heterocyclic synthesis intermediate, medicinal chemistry building block, structure-activity relationship (SAR) studies
Compound Overview and Chemical Properties
6-Cyclohexyl-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile (Aladdin SKU: C699963) belongs to the dihydropyrimidine (DHPM) family of heterocyclic compounds. The DHPM scaffold is classically assembled via the Biginelli multicomponent condensation reaction, which combines an aldehyde, a 1,3-dicarbonyl compound, and urea or thiourea under acidic conditions.
The molecule features three electronically significant substituents: (1) a thioxo group (C=S) at the C-2 position, which confers nucleophilic reactivity toward electrophilic alkylating agents; (2) a nitrile group (C≡N) at C-5, offering a handle for further elaboration via cycloaddition, hydrolysis, or reduction; and (3) a cyclohexyl group at C-6, providing lipophilic bulk that may influence membrane permeability and binding pocket interactions in biological targets.
These combined features make the compound a multifunctional building block in the preparation of fused heterocyclic systems, thioether derivatives, and aminopyrimidine analogues relevant to drug discovery programs.
Materials, Safety and Pre-Protocol Checklist
Materials required:
- 6-Cyclohexyl-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile (C699963, Aladdin Scientific)
- Analytical balance (readability ≤ 0.1 mg)
- Appropriate anhydrous organic solvents (e.g., DMSO, DMF, or ethanol; see solubility note below)
- Amber glass vials with PTFE-lined caps
- Nitrogen or argon gas line for inert-atmosphere handling
- Personal protective equipment (PPE): nitrile gloves, lab coat, safety glasses
- Chemical fume hood
Safety precautions: Handle in a well-ventilated fume hood. The thioxo and nitrile functional groups may pose irritation hazards. Consult the Safety Data Sheet (SDS) for C699963 before use. Avoid inhalation of dust and contact with skin or eyes. Dispose of waste according to local regulations for organic sulfur-containing compounds.
Solubility guidance: Thioxo-DHPM compounds of this class are generally sparingly soluble in water. Polar aprotic solvents such as DMSO or DMF are commonly used to prepare stock solutions. Verify solubility empirically for your specific application and buffer system. Filter through a 0.22 µm membrane if preparing solutions for cell-based assays.
Note: Specific solubility values for C699963 are not confirmed in current source material; experimental verification is recommended.
Step-by-Step Protocol: Stock Solution Preparation and Downstream Use
Step 1 – Equilibrate to room temperature. Remove the reagent vial from storage and allow it to equilibrate to room temperature (approx. 20–25 °C) in a sealed container before opening. This prevents condensation of atmospheric moisture onto the solid.
Step 2 – Weigh accurately. Tare an amber glass vial on the analytical balance. Transfer the required mass of C699963 using a clean spatula. Record the exact mass.
Step 3 – Dissolve in appropriate solvent. Add anhydrous DMSO (or DMF) dropwise to the weighed solid, vortexing gently between additions. For a 10 mM stock, calculate the required solvent volume using the molecular weight of the compound. Sonicate briefly (1–2 min) in an ultrasonic bath if complete dissolution is slow.
Step 4 – Verify dissolution. Inspect the solution visually. The solution should be clear and free from particulates. If turbidity persists, warm gently to 37–40 °C briefly and re-vortex. Filter through a 0.22 µm PTFE syringe filter if necessary.
Step 5 – Aliquot and store. Divide the stock solution into single-use aliquots in amber microcentrifuge tubes under inert gas. Store at –20 °C or as indicated by the SDS. Avoid repeated freeze-thaw cycles.
Step 6 – Working solution preparation. Dilute stock to the desired working concentration using the assay-compatible vehicle. Keep the final DMSO concentration ≤ 0.1% (v/v) for cell-based assays unless otherwise validated, to minimise vehicle effects.
Step 7 – Downstream synthetic use. For use as a heterocyclic building block in synthesis (e.g., alkylation at C-2 sulfur, cyclocondensation via the nitrile, or C-5 functionalisation), follow established literature procedures for DHPM-thione chemistry. Conduct reactions under inert atmosphere when using moisture-sensitive reagents.
Troubleshooting and Quality Control
Poor solubility: If the compound fails to dissolve completely in DMSO, increase the solvent volume to lower the concentration, apply mild sonication, or switch to DMF. Do not attempt to dissolve in aqueous buffers alone, as DHPM-thiones of this class typically have low aqueous solubility.
Solution discoloration: Freshly prepared solutions should be pale yellow to colourless. Significant darkening may indicate decomposition. Discard discoloured solutions and prepare fresh stock from intact solid. Protect solutions from prolonged light exposure.
Unexpected reaction outcomes in synthesis: The C-2 thioxo group can tautomerise between thione and thiol forms. Ensure reaction conditions are optimised for the desired tautomeric form. If alkylation at sulfur is intended, mildly basic conditions typically favour the thiolate anion.
Purity verification: Confirm compound identity and purity by TLC, HPLC, or NMR prior to use in critical assays. Aladdin Scientific provides a certificate of analysis (CoA) with each lot; verify lot-specific purity data before use.
Moisture sensitivity: Though not classified as highly moisture-sensitive, prolonged exposure of the solid to humid air may cause surface adsorption. Always reseal under inert gas after use.
Frequently asked questions
What solvents are recommended for preparing stock solutions of C699963?
Polar aprotic solvents such as DMSO or DMF are recommended for preparing stock solutions of this DHPM-thione compound, as aqueous solubility is expected to be low for compounds of this structural class. Always verify solubility experimentally and filter through a 0.22 µm membrane before use in cell-based assays.
How should 6-Cyclohexyl-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile be stored to maintain stability?
Store the solid in a cool, dry, and well-ventilated location protected from moisture and direct light. Stock solutions prepared in DMSO should be aliquoted into single-use portions, stored at –20 °C under inert gas, and protected from repeated freeze-thaw cycles. Refer to the SDS and certificate of analysis for lot-specific storage recommendations.
What are the main synthetic applications of this DHPM-thione building block?
The compound serves as a versatile intermediate in heterocyclic chemistry. The C-2 thioxo group can undergo S-alkylation to generate thioether derivatives, the C-5 nitrile can be exploited in cycloaddition reactions or hydrolysis to amides, and the DHPM core can be further elaborated for structure-activity relationship (SAR) studies in medicinal chemistry programs targeting biologically relevant scaffolds.
Is the compound suitable for use in cell-based biological assays?
This compound may be evaluated in cell-based assays; however, the final vehicle (DMSO) concentration should be maintained at ≤ 0.1% (v/v) to minimise cytotoxic vehicle effects. Purity should be confirmed from the CoA, and the compound solution should be sterilised by 0.22 µm filtration. Specific biological activity data for C699963 are not confirmed in current source material and should be verified in the scientific literature or by in-house testing.
References
- Kappe, C. O. (1993). A reexamination of the mechanism of the Biginelli dihydropyrimidine synthesis. Support for an acyliminium ion intermediate. Journal of Organic Chemistry, 58(20), 5453–5459.
- Kappe, C. O. (2000). Biologically active dihydropyrimidones of the Biginelli-type — a literature survey. European Journal of Medicinal Chemistry, 35(12), 1043–1052.
- Atwal, K. S. et al. (1991). Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents. Journal of Medicinal Chemistry, 34(2), 806–811.
Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
危险品化学品经营许可证(带存储)